Gómez-Sepúlveda ME, Rentería-Jiménez M

Language: Spanish
References: 16
Page:
PDF size: 398.15 Kb.

ABSTRACT

Human papillomavirus (HPV) is one of the main sexually transmitted infections and remains one of the main risk factors for the development of cervical cancer. HPV infection is most often asymptomatic and goes unnoticed in immunocompetent people. For the development of cervical intraepithelial neoplasias (CIN) that can progress to invasive cancer, there needs to be a persistent HPV infection, especially HPV types 16 and 18, which are associated with squamous cell carcinoma and cervical adenocarcinoma, respectively. For diagnosis, there are currently many tools apart from cervical cytology, such as HPV DNA, which is currently used in conjunction with cytology for screening and studies have currently been carried out to use it as a primary screening test. Treatment depends on the degree of the lesion, with ablation or excision procedures being those indicated for CIN2 or 3. Primary prevention through vaccination has been an important factor in reducing the risk of cancer associated with HPV, although it continues to be a public health problem worldwide, especially in developing countries.

REFERENCES

1. Mac M, Moody CA. Epigenetic regulation of thehuman papillomavirus life cycle. Vol. 9,Pathogens. MDPI AG; 2020. p. 1–18.

2. CDC. Cancers Linked With HPV Each Year. 2023.

3. CENETEC. Prevención, detección, diagnóstico ytratamiento de lesiones precursoras del cáncerde cuello uterino en primer y segundo grado denivel de atención. Guía de evidencias yrecomendaciones. Guía de práctica clínica.2018;

4. Vonsky M, Shabaeva M, Runov A, Lebedeva N,Chowdhury S, Palefsky JM, et al. CarcinogenesisAssociated with Human Papillomavirus Infection.Mechanisms and Potential for Immunotherapy.Vol. 84, Biochemistry (Moscow). Pleiadesjournals; 2019. p. 782–99.

5. Bedell SL, Goldstein LS, Goldstein AR, GoldsteinAT. Cervical Cancer Screening: Past, Present,and Future. Sex Med Rev. 2020 Jan1;8(1):28–37.

6. Palefski J. Human Papillomavirus infections:epidemiology and disease associations. 2022.

7. Kusakabe M, Taguchi A, Sone K, Mori M, OsugaY. Carcinogenesis and management of humanpapillomavirus-associated cervical cancer. Int JClin Oncol [Internet]. 2023 Aug 1 [cited 2024Jun 7];28(8):965. Available from:/pmc/articles/PMC10390372/

8. Aggarwal S, Agarwal P, Singh AK. Humanpapilloma virus vaccines: A comprehensivenarrative review. Cancer Treat Res Commun.2023 Jan 1;37:100780.

9. Chan CK, Aimagambetova G, Ukybassova T,Kongrtay K, Azizan A. Human PapillomavirusInfection and Cervical Cancer: Epidemiology,Screening, and Vaccination - Review of CurrentPerspectives. Vol. 2019, Journal of Oncology.Hindawi Limited; 2019.

10. Della Fera AN, Warburton A, Coursey TL,Khurana S, McBride AA. Persistent humanpapillomavirus infection. Vol. 13, Viruses. MDPIAG; 2021.

11. Manini I, Montomoli E. Epidemiology andprevention of Human Papillomavirus. Ann Ig.2018;30(4):28–32.

12. Rahangdale L, Mungo C, O’Connor S, ChibweshaCJ, Brewer NT. Human papillomavirusvaccination and cervical cancer risk. BMJ[Internet]. 2022 Dec 15 [cited 2024 Jun 7];379.Available from:https://www.bmj.com/content/379/bmj-2022-070115

13. Kaliterna V, Barisic Z. Genital humanpapillomavirus infections. Vol. 23, Frontiers InBioscience. 2018.

14. Burmeister CA, Khan SF, Schäfer G, Mbatani N,Adams T, Moodley J, et al. Cervical cancertherapies: Current challenges and futureperspectives. Tumour Virus Res. 2022 Jun1;13:200238.

15. Curry SJ, Krist AH, Owens DK, Barry MJ,Caughey AB, Davidson KW, et al. Screening forcervical cancer us preventive services task forcerecommendation statement. JAMA - Journal ofthe American Medical Association. 2018 Aug21;320(7):674–86.

16. Feldman S, Crum C. Cervical cancer screeningtests: Techniques for cervical cytology andhuman papillomavirus testing. 2023.